In reply: We thank Inglis and colleagues1 for their interest in our review article2 and for highlighting the important issue of a possible signal for increased thyroid cancer risk with glucagon‐like peptide 1 (GLP‐1) receptor agonists raised in the study by Bezin and colleagues.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Inglis JM, Kichenadasse G, Mangoni AA. Current and emerging medications for the management of obesity in adults [letter]. Med J Aust 2023; 219: 187‐188.
- 2. Walmsley R, Sumithran P. Current and emerging medications for the management of obesity in adults. Med J Aust 2023; 218: 276‐283. https://www.mja.com.au/journal/2023/218/6/current‐and‐emerging‐medications‐management‐obesity‐adults
- 3. Bezin J, Gouverneur A, Pénichon M, et al. GLP‐1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384‐390.
- 4. Thompson CA, Stürmer T. Putting GLP‐1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 2022; 46: 249‐251.
- 5. Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). J Natl Cancer Inst 2020; 112: 810‐817.
- 6. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon‐like peptide‐1 receptor agonists activate rodent thyroid C‐cells causing calcitonin release and C‐cell proliferation. Endocrinology 2010; 151: 1473‐1486.
- 7. Sattar N, Lee M, Kristensen S, et al. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: a systematic review and meta‐analysis of randomised trials. Lancet Diab Endocrinol 2021; 9: 653‐662.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Priya Sumithran is supported by an Investigator Grant from the National Health and Medical Research Council (1178482).
Priya Sumithran has co‐authored manuscripts that have had medical writing assistance provided (Novo Nordisk). No medical writing assistance was received for this manuscript. Priya Sumithran is in the leadership group of the Obesity Collective.